Fatal hepatic veno-occlusive disease in a phase I study of Mylotarg and Troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome

Acta Haematologica

Volumn 108, Issue 3, 2002, Pages 164-167

  Giles, Francis ^a   Garcia Manero, Guillermo ^a   O'brien, Susan ^a   Estey, Elihu ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CD33 ANTIGEN; CREATININE; GEMTUZUMAB OZOGAMICIN; STEROID; TROXACITABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; ASCITES; BONE MARROW; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DRUG EFFECT; DRUG MECHANISM; FATALITY; FEMALE; FLUID RETENTION; HEPATOMEGALY; HUMAN; HYPERBILIRUBINEMIA; LIVER DISEASE; LIVER VENOOCCLUSIVE DISEASE; MALE; MYELODYSPLASTIC SYNDROME; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; STEROID THERAPY; THROMBOCYTE; TREATMENT OUTCOME; WEIGHT GAIN;

ACUTE DISEASE; AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CYTOSINE; DIOXOLANES; FEMALE; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES;

EID: 0036424141     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000064700     Document Type: Article

References (13)

1. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R: Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001;7:1490-1496.
2. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bern-stein ID, Appelbaum FR: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001;19:3244-3254.
3. Sievers EL, Larson RA, Estey E, et al: Low incidence of hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (My-lotarg, CMA-676): Relationship to hematopoietic stem cell transplantation. Blood 2000; 96:206b.
4. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB: Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002;99:2310-2314.
5. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH: Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic veno-occlusive disease in patients who have not received stem cell transplantation. Cancer 2001;92:406-413.
6. Neumeister P, Eibl M, Zinke-Cerwenka W, Scarpatetti M, Sill H, Linkesch W: Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate. Ann Hematol 2001;80:119-120.
7. Bearman SI: The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995;85:3005-3020.
8. Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, O'Brien SM, Thomas DA, Andreeff M, Bivins C, Jolivet J, Kantarjian HM: Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol 2002;20:656-664.
9. Giles FJ: Novel agents for the therapy of acute leukemia. Curr Opin Oncol 2002;14:3-9.
10. Giles FJ, Cortes JE, Baker SD, Thomas DA, O'Brien S, Smith TL, Beran M, Bivins C, Jolivet J, Kantarjian HM: Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol 2001;19:762-771.
11. de Bono JS, Stephenson J Jr, Baker SD, Hidalgo M, Patnaik A, Hammond LA, Weiss G, Goetz A, Siu L, Simmons C, Jolivet J, Rowinsky EK: Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 2002;20:96-109.
12. Dowell JA, Berger MS, King SP, Korth-Bradley J, Liu H: The pharmacokinetics of gemtuzumab ozogamicin: An antibody-targeted chemotherapy agent for relapsed acute myeloid leukemia. Blood 2000;96:120a.
13. Blakolmer K, Jaskiewicz K, Dunsford HA, Robson SC: Hematopoietic stem cell markers are expressed by ductal plate and bile duct cells in developing human liver. Hepatology 1995; 21:1510-1516.